

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 201 240 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.05.2002 Bulletin 2002/18

(51) Int Cl.7: A61K 31/41, A61K 31/4245,
A61K 31/433, C07D 257/04,
C07D 271/07, C07D 285/08,
C07D 291/04, A61P 25/00,
A61P 25/08, A61P 25/28,
A61P 25/22, A61P 29/00,
A61P 1/00, A61P 25/24

(21) Application number: 01308061.9

(22) Date of filing: 21.09.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 31.10.2000 GB 0026578

(71) Applicant: WARNER-LAMBERT COMPANY
Morris Plains New Jersey 07950 (US)




(72) Inventors:

- Bryans, Justin Stephen
Balsham, Cambridgeshire CB1 6DZ (GB)
- Williams, Sophie Caroline
Cambridge, Cambridgeshire CB1 7TX (GB)
- Blakemore, David Clive
Cambridge, Cambridgeshire CB1 8TH (GB)

(74) Representative: Cole, Paul
Lucas & Co.,
135 Westhall Road
Warlingham, Surrey CR6 9HJ (GB)

(54) Heterocyclic derivatives useful as pharmaceutical agents

(57) This invention relates to novel heterocyclic derivatives of the formula (VII), (VIII) or (IX)



in which P, Q, R¹ - R⁶, m and n are as defined in the specification, and to pharmaceutically acceptable salts thereof. The compounds and pharmaceutical compositions containing them are useful in the treatment of a range of disorders including epilepsy, faintness attacks, hypokinesia, cranial disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases and gastrointestinal disorders, especially irritable bowel syndrome.

EP 1 201 240 A2


Description**FIELD OF THE INVENTION**

5 [0001] This invention relates to novel heterocyclic derivatives useful as pharmaceutical agents, to processes for their production, to pharmaceutical compositions containing them, and to their use for the treatment of the neurological conditions set out below.

BACKGROUND TO THE INVENTION


10 [0002] Gabapentin (Neurontin®) is an anti-convulsant agent that is useful in the treatment of epilepsy and that has recently been shown to be a potential treatment for neurogenic pain. It is 1-(aminomethyl)-cyclohexylacetic acid of structural formula:

15



20

25 [0003] Gabapentin is one of a series of compounds of formula




30

35 in which R_1 is hydrogen or a lower alkyl radical and n is 4, 5, or 6. These compounds are described US-A-4,024,175 and its divisional US-A-4,087,544. Their disclosed uses are: the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The disclosures of the above two patents are hereby incorporated by reference.


40 [0004] WO 97/33858 whose disclosure is incorporated herein by reference describes novel substituted cyclic amino acids, their derivatives, prodrugs and pharmaceutically acceptable salts that are of the formula:

45



50 in which R^1 to R^{10} are each independently selected from straight or branched chain C^1 - C^6 alkyl, substituted or unsubstituted benzyl or phenyl which substituents are selected from halogen, alkoxy, alkyl, hydroxy, carboxy, carboalkoxy, trifluoromethyl and nitro, any of R^1 to R^{10} which is not one of the above being hydrogen. They are useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders.

55 [0005] WO 99/21824, whose disclosure is also incorporated by reference, discloses further cyclic amino acids that are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammation, especially arthritis. The compounds disclosed include those of the formula:




10 and salts thereof, in which:

R is hydrogen or a lower alkyl;

15 R¹ to R⁸ are each independently selected from hydrogen, straight or branched alkyl of from 1 to 6 carbons, phenyl, benzyl, fluorine, chlorine, bromine, hydroxy, hydroxymethyl, amino, aminomethyl, trifluoromethyl, -CO₂H, -CO₂R¹⁵, -CH₂CO₂H, -CH₂CO₂R¹⁵, -OR¹⁵ wherein R¹⁵ is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or benzyl, and R¹ to R⁸ are not simultaneously hydrogen.

20 [0006] US-A-5563175 whose disclosure is incorporated herein by reference describes compounds of the formula (V)




in which:

30 R¹ represents straight or branched C₁ - C₆ alkyl, C₃ - C₆ cycloalkyl or phenyl;

R² represents hydrogen or methyl; and

R³ represents hydrogen, methyl or carboxyl.

35 [0007] The compounds of formula (V) (including their pharmaceutically acceptable salts) are structural analogues of γ -aminobutyric acid (GABA) and were stated to activate L-glutamic acid decarboxylase (GAD), to bind to a novel binding site, to be useful in anti-seizure therapy for central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischemia, Parkinson's disease, tardive dyskinesia and spasticity, and also to exhibit antidepressant, anxiolytic and antipsychotic activity. The most preferred compounds were those where R³ and R² were hydrogen and R¹ was isobutyl, the (S)-(+)-enantiomer of formula (VI) being the most preferred.



45 [0008] That compound is variously called 4-amino-3-(2-methylpropyl)butanoic acid, 3-(aminomethyl)-5-methylhexanoic acid, β -isobutyl- γ -aminobutyric acid, isobutyl-GABA, isobutylgaba and pregabalin.

50 [0009] US-A-6001876 discloses that the above compounds are useful in pain therapy. US-A-5840956 discloses methods for making (\pm)-isobutylgaba and for obtaining from it (S)-isobutylgaba. The disclosure of these specifications is also incorporated herein by reference.

55 [0010] WO 99/31075 and WO 99/31074 whose disclosures are incorporated herein by reference describe *inter alia* heterocyclic analogs of the compounds of formulae (III), (IV) and (V) in which a biostERICALLY equivalent group having


acid hydrogen attached to a ring amine group replaces the carboxyl moiety. The analogs are stated to be useful as agents in the treatment of *inter alia* epilepsy, faintness attacks, hypokinesia, cranial disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases and gastrointestinal disorders, especially irritable bowel syndrome. The following compounds are disclosed as intermediates in WO 99/31075:

[1-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester; and [1-(5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester. The following compounds are disclosed as intermediates in WO 99/31074: 4-methyl-2-(1H-tetrazol-5-ylmethyl)pentyl-carbamic acid tert-butyl ester; BOC-isobutyl GABA oxadiazolonethione; and BOC-isobutyl GABA oxadiazolone.

SUMMARY OF THE INVENTION


[0011] A problem with which this invention is concerned is the production of pharmaceutical compositions and active compounds useful in the manner of the heterocyclic compounds of WO 99/31075 and WO 99/31074, especially in pain therapy, that when administered to humans or other animals provide an increased duration of active ingredient in the plasma.

[0012] That problem is unexpectedly solved, according to the invention, by a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula (VII), (VIII) or (IX) or a pharmaceutically acceptable salt thereof:



35 in which:

P is hydrogen or methyl;
 Q is a labile amine- or amide-forming organic group that becomes removed in the human or animal, especially mammal, body;
 40 R¹ is a heterocycle selected from:



50 R² represents methyl; and
 the groups R³ (which when n is 2 may be the same or different) represent C₁ - C₆ alkyl;
 R⁴ is straight or branched C₁ - C₆ alkyl, C₃ - C₆ cycloalkyl or phenyl;
 R⁵ is hydrogen or methyl;
 R⁶ is hydrogen, methyl or carboxyl;
 55 m is an integer from 0 to 2; and
 n is an integer from 0 to 2.

[0013] Most of the compounds of the above formulae are new. The invention also relates to a compound of any of

the formulae (VII), (VIII) or (IX) as defined in above or a pharmaceutically acceptable salt thereof, subject to the proviso that said compound is other than:

5 [1-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester;
 [1-(5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester;
 4-methyl-2-(1H-tetrazol-5-ylmethyl)pentyl-carbamic acid tert-butyl ester;
 BOC-isobutyl GABA oxadiazolonethione; and
 BOC-isobutyl GABA oxadiazolone.

10 [0014] It is believed that a pro-drug of the formula (VII), (VIII) or (IX) when administered to a human or other animal, especially a mammal, enters the bloodstream by passive diffusion along the whole length of the intestine, which gives a much longer duration of effectiveness. The pro-drug may not itself be biologically active, but decomposes to the corresponding active compound in plasma.


15 [0015] Certain of the compounds of formula (VII), (VIII) or (IX) can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are biologically equivalent to unsolvated forms and are encompassed within the scope of the invention. Certain of the compounds of the invention possess one or more chiral centers and each center may exist in the R or S configuration. The invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. It also includes salts of any of the above compounds with physiologically acceptable cations or anions.

20 [0016] The invention also provides a method for making a compound of the formula (VII), (VIII) or (IX) above, which comprises:

coupling a compound of the formula:

25

30




35

in which P and R^1 - R^6 have the meanings given above and in which said compound is in the form of a free base or an ammonium salt with a compound of the formula (XIII)

40

45



or QCl , where (in each case) Q has the meaning given above.

50 [0017] The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (VII), (VIII) or (IX) above and a pharmaceutically acceptable carrier.

[0018] In a further aspect the invention provides the use of a compound of formula (VII), (VIII) or (IX) in the manufacture of a medicament for the treatment of any of the following:

55 epilepsy; a faintness attack;
 hypokinesia; a cranial disorder;
 a neurodegenerative disorder; depression;
 anxiety; panic;
 pain; a neuropathological disorder;


a digestive disorder.

5 [0019] In a further aspect, the invention provides a method for treating any of the above disorders which comprises administering a therapeutically effective amount of a compound of formula (VII), (VIII) or (IX) to a human or animal in need of said treatment.

DESCRIPTION OF PREFERRED FEATURES

Preferred values for Q

10 [0020] The group Q may be one that can be removed hydrolytically under physiological conditions, in which case it may be




20

in which:

R7 is hydrogen, straight or branched chain C₁ - C₆ alkyl, phenyl or benzyl in which the benzene ring may be substituted or unsubstituted; and

25 Y is hydrogen, straight or branched chain C₁ - C₆ alkyl, or -CH₂CO₂R8 in which R8 represents straight or branched chain C₁ - C₆ alkyl

30 [0021] Alternatively, the group Q may be one which can be removed enzymatically under physiological conditions, in which case it may be selected from




40

in which:

R9 is hydrogen, straight or branched chain, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted; and

45 X, X1 and X2 represent a phenyl group or any of the side chains of the 20 naturally encoded α -amino acids.

[0022] In a preferred group of compounds Q is



55 wherein R10 is C₁ - C₆ alkyl (preferably methyl or t-butyl) or phenyl.

Active compounds providing the basis of pro-drugs

[0023] Pro-drugs according to the invention and of formulae (VII) and (VIII) may be produced corresponding to the following compounds disclosed in WO 99/31075, the -NH₂ group being replaced by a -NPQ group, where P and Q have the meanings given above:

Tetrazoles

[0024]

C-[1-(1H-Tetrazol-5-ylmethyl)-cyclohexyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclohexyl]methylamine;
 C-[1-(1H-Tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (trans)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1R-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1R-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1S-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (S)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (R)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine.

Oxadiazolones

[0025]

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one.

[1,2,4]Oxadiazole-5-thiones

[0026]

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-[1,2,4]oxadiazol-5-thione.

[1,2,4]Thiadiazol-5-ones

[0027]

5 3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 10 (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 15 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one.

Oxathiadiazoles

[0028]

20 C-[1-(2-Oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;
 25 C-[1-(2-Oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (trans)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (1R-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (1R-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 30 (1S-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methyl-
 amine;
 (1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methyl-
 amine;
 35 (S)C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (R)C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine.

[0029] Of the above compounds, C-[1-(1H-tetrazol-5-ylmethyl)cyclohexyl]-methylamine and 4-methyl-2-(1H-tetra-
 zol-5-ylmethyl)-pentylamine are at present preferred.

40 Compounds of formula (IX)

[0030] Pro-drugs of formula (IX) may be made corresponding e.g. to any of the following compounds disclosed in
 WO 99/31074:

45 4-methyl-2-(1H-tetrazol-5-ylmethyl)-pentylamine;
 3-(2-aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazol-5-one, HCl;
 3-(2-aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazol-5-thione, HCl;
 3-(3-amino-2-cyclopentyl-propyl)-4H-[1,2,4]oxadiazol-5-one.
 50 2-cyclopentyl-3-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-yl propylamine.

Preparative methods

[0031] Various methods may be used to prepare compounds according to the invention from starting materials of
 formulae (X), (XI) or (XII). For example, an amide prodrug of any the above starting materials may be prepared by
 reacting the starting material with an acid chloride in an ether e.g. tetrahydrofuran at ambient temperatures. An (acyloxy)
 alkyl carbamate prodrug of the above starting materials may be prepared by reacting the starting material with an
 acyloxyalkyl *p*-nitrophenyl carbonate in an ether e.g. tetrahydrofuran at ambient temperatures.

Use of the compounds

[0032] The compounds of the invention are expected to be useful in the treatment of epilepsy. They may also be used as mimetic agents for neurodegenerative disorders. Such neurodegenerative disorders are, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. The present invention also covers treating acute brain injuries. These include but are not limited to: stroke, head trauma, and asphyxia. Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke. Stroke includes both focal and global ischemia. Also, included are transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia such as in a patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like. Other incidents are head trauma, spinal cord trauma, or injury from general anoxia, hypoxia, hypoglycemia, hypotension as well as similar injuries seen during procedures from embolus, hyperfusion, and hypoxia. Treatment with the present compounds could also be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus. A skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as suffering from stroke for administration by methods of the present invention.

[0033] The compounds of the invention are also expected to be useful in the treatment of depression. Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a mechanistic cause for at least some forms of depression. The diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt. The standards for diagnosis of depression as well as all psychiatric diagnoses are collected in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) referred to as the DSM-IV-R manual published by the American Psychiatric Association, 1994.

[0034] The present compounds are also expected to be useful in the treatment of anxiety and of panic as demonstrated by means of standard pharmacological procedures.

[0035] The compounds of the invention are also expected to be useful in the treatment of pain. Pain refers to acute as well as chronic pain. Acute pain is usually short-lived and is associated with hyperactivity of the sympathetic nervous system. Examples are postoperative pain and allodynia. Chronic pain is usually defined as pain persisting from 3 to 6 months and includes somatogenic pains and psychogenic pains. Other pain is nociceptive. Still other pain is caused by injury or inflammation of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from. Psychogenic pain is that which occurs without an organic origin such as low back pain, atypical facial pain, and chronic headache. Other types of pain are: inflammatory pain, osteoarthritic pain, trigeminal neuralgia, cancer pain, diabetic neuropathy, restless leg syndrome, acute herpetic and postherpetic neuralgia, causalgia, brachial plexus avulsion, occipital neuralgia, gout, phantom limb, burn, and other forms of neuralgia, neuropathic and idiopathic pain syndrome.

[0036] The present compounds are also expected to be useful in the treatment of digestive disorders such as visceral pain, pain associated with cancer, the irritable bowel syndrome, infection and inflammation.

Dosage forms

[0037] The present compounds can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, they can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, they can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component either a compound of the invention or a corresponding pharmaceutically acceptable salt. Oral dosage forms are preferred, but parenteral dosage forms may also be used where it is desired to use the kinetics of decomposition into the corresponding active compound.

[0038] For preparing pharmaceutical compositions from the present compounds, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring

agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

[0039] In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about 5 seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, 10 powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0040] For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

[0041] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol.

[0042] Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

[0043] Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in 20 water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

[0044] Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form 25 preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0045] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided 30 into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0046] The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component. In medical use the drug may be administered three times daily as, for example, capsules of 100 or 300 mg. The composition can, if desired, also contain other compatible therapeutic agents.


[0047] In therapeutic use, the compounds utilized in the pharmaceutical method of this invention are administered 35 at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 100 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular 40 situation is within the skill of the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

PREPARATION OF REAGENTS

[0048] Preparation of reagents for making pro-drug according to the invention is set out below.

Acetoxymethyl -nitrophenyl carbonate (1)

[0049]




[0050] Carbonate 1 was prepared as described in *J.Med.Chem.*, 1988, **31**, 318-322 (5.29 g, 98%). Its characteristics were described in *J.Org.Chem.*, 1997, **62**, 1356-1362.

5 ν_{max} (film)/cm⁻¹ 1776 (C=O), 1526 (C=C, Ar).

δ_{H} (400 MHz; CDCl₃) 2.19 (3H, s, CH₃), 5.88 (2H, s, OCH₂O), 7.42 (2H, d, *J* 9.6, *p*-NO₂ArH), 8.30 (2H, d, *J* 9.2, *p*-NO₂ArH).

10 **2,2-dimethylpropionyloxymethyl *p*-nitrophenyl carbonate (2)**

15 [0051]




20 [0052] Carbonate 2 was also prepared as described in the above paper (1.16 g, 60%).

25 ν_{max} (film)/cm⁻¹ 1779, 1759 (C=O), 1530 (C=C, Ar).

δ_{H} (400 MHz; CDCl₃) 1.26 (9H, s, *t*butyl), 5.89 (2H, s, OCH₂O), 7.41 (2H, d, *J* 9.4, *p*-NO₂ArH), 8.30 (2H, d, *J* 9.2, *p*-NO₂ArH).

25 **Benzoyloxymethyl *p*-nitrophenyl carbonate (3)**

30 [0053]




40 [0054] Carbonate 3 was also prepared as described in the above paper (1.76 g, 85%).

45 ν_{max} (film)/cm⁻¹ 1778, 1740 (C=O), 1525 (C=C Ar).

δ_{H} (400 MHz; CDCl₃) 6.14 (2H, s, OCH₂O), 7.42 (2H, d, *J* 9.2, *p*-NO₂ArH), 7.49 (2H, t, *J* 8.0, ArH), 7.64 (1H, t, *J* 7.6, ArH), 8.12 (2H, d, *J* 7.2, ArH) 8.29 (2H, d, *J* 9.2, *p*-NO₂ArH).

45 [0055] The invention will now be further described with reference to the following examples:

50 Example 1.



[0056] The starting 1-(1H-tetrazol-5-ylmethyl)-cycohexanecarbonitrile was synthesized as described in WO 9931075. The tetrazole (200mg, 1.026mmol) was suspended in dry dichloromethane (10ml) and stirred under nitrogen with triethylamine (340 μ l, 2.58mmol) and benzoyl chloride (133mg, 0.95mmol). After 24 hours, the mixture was diluted with dichloromethane (20ml) and washed with 2N HCl (aq) (20ml). The organic phase was collected, dried ($MgSO_4$) and the solvent removed *in vacuo* to give 225mg (73%) of the desired product as a white solid.


[0057] 1H NMR ($CDCl_3$, 400MHz) δ : 1.17-1.80 (10H, m), 2.97 (2H, s), 3.34 (2H, d, $J=7$ Hz), 6.74 (1H, br. S), 7.44-7.61 (3H, m), 7.84 (2H, m).

[0058] MS (AP $^+$) m/e: 300 (MH^+ , 100%).

10

Example 2.

15



20

[0059] The above tetrazole (200mg, 1.026mmol) was suspended in dry dichloromethane (10ml) and stirred under nitrogen with triethylamine (340 μ l, 2.58mmol) and trimethylacetyl chloride (115mg, 0.95mmol). After 24 hours, the mixture was diluted with dichloromethane (20ml) and washed with 2N HCl (aq) (20ml). The organic phase was collected, dried ($MgSO_4$) and the solvent removed *in vacuo* to give 211 mg (74%) of the desired product as a white solid.


[0060] 1H NMR ($CDCl_3$, 400MHz) δ : 1.06-1.79 (10H, m), 1.28 (9H, s), 2.83 (2H, s), 3.11 (2H, d, $J=7$ Hz), 6.10 (1H, br. S).

[0061] MS (AP $^+$) m/e: 280 (MH^+ , 100%).

35

Example 3

40



45

[0062] The above tetrazole (200mg, 1.026mmol) was suspended in dry dichloromethane (10ml) and stirred under nitrogen with triethylamine (340 μ l, 2.58mmol) and acetyl chloride (75mg, 0.95mmol). After 24 hours, the mixture was diluted with dichloromethane (20ml) and washed with 2N HCl (aq) (20ml). The organic phase was collected, dried ($MgSO_4$) and the solvent removed *in vacuo* to give 129mg (51%) of the desired product as a white solid.

[0063] 1H NMR ($CDCl_3$, 400MHz) δ : 1.08-1.77 (10H, m), 2.16 (3H, s), 2.90 (2H, s), 3.12 (2H, d, $J=7$ Hz), 6.07 (1H, br. S).

[0064] MS (AP $^+$) m/e: 238 (MH^+ , 100%).


55

Claims



1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective

amount of a compound of the formula (VII), (VIII) or (IX) or a pharmaceutically acceptable salt thereof:

5



10



15

in which:


P is hydrogen or methyl;

Q is a labile amine- or amide-forming organic group that becomes removed in the human or animal, especially mammal, body;

20

R¹ is a heterocycle selected from:

25



R² represents methyl;

30

the groups R³ (which n is 2 may be the same or different) represent C₁ - C₆ alkyl;

R⁴ is straight or branched C₁ - C₆ alkyl, C₃ - C₆ cycloalkyl or phenyl;

R⁵ is hydrogen or methyl;

R⁶ is hydrogen, methyl or carboxyl;


m is an integer from 0 to 2; and

35

n is an integer from 0 to 2.

2. The composition of claim 1, wherein P in the compound of the formula (VII), (VIII) or (IX) is hydrogen.
3. The composition of claim 1 or 2, wherein Q in the compound of the formula (VII), (VIII) or (IX) can be removed hydrolytically under physiological conditions.
4. The composition of claim 3, wherein Q in the compound of the formula (VII), (VIII) or (IX) is

45



50

in which:

R⁷ is hydrogen, straight or branched chain C₁ - C₆ alkyl, phenyl or benzyl in which the benzene ring may be substituted or unsubstituted; and

55

Y is hydrogen, straight or branched chain C₁ - C₆ alkyl, or -CH₂CO₂R⁸ in which R⁸ represents straight or branched chain C₁ - C₆ alkyl.


5. The composition of claim 1 or 2, wherein Q in the compound of the formula (VII), (VIII) or (IX) can be removed

enzymatically under physiological conditions.

6. The composition of claim 5, wherein the group Q in the compound of the formula (VII), (VIII) or (IX) is selected from

5

10



15


in which:

R⁹ is hydrogen, straight or branched chain, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted; and
 X, X¹ and X² represent a phenyl group or any of the side chains of the 20 naturally encoded α -amino acids.

20

7. The composition of claim 6, wherein Q in the compound of the formula (VII), (VIII) or (IX) is

25



wherein R¹⁰ is C₁ - C₆ alkyl (preferably methyl or t-butyl) or phenyl.

30

8. The composition of claim 7, wherein R¹⁰ in the above compound is methyl or t-butyl.

9. The composition of any preceding claim, wherein the compound of the formula (VII), (VIII) or (IX) is a tetrazole pro-drug in which the -NH₂ group of any compound listed below is replaced by a -NPQ group, where P and Q have the meanings given above:

35

C-[1-(1H-Tetrazol-5-ylmethyl)-cyclohexyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclohexyl]methylamine;
 C-[1-(1H-Tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (trans)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1R-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1R-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1S-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (S)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 (R)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-methylamine.

40

10. The composition of any of claims 1-8, wherein the compound of the formula (VII), (VIII) or (IX) is an oxadiazolone pro-drug in which the -NH₂ group of any compound listed below is replaced by a -NPQ group, where P and Q have the meanings given above:

45

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

5 (1R-cis)3-(1-Aminomethyl-3 -methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1S-trans)3-(1-Aminomethyl-3 -methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1 α ,3 α ,4 α)3-(1 -Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one.

10 11. The composition of any of claims 1-8, wherein the compound of the formula (VII), (VIII) or (IX) is a [1,2,4]oxadiazole-5-thione pro-drug in which the -NH₂ group of any compound listed below is replaced by a -NPQ group, where P and Q have the meanings given above:

15 3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (trans)3 -(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1R-trans)3-(1-Aminomethyl-3 -methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 20 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-thione;
 25 3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-[1,2,4]oxadiazol-5-thione.

30 12. The composition of any of claims 1-8, wherein the compound of the formula (VII), (VIII) or (IX) is a [1,2,4]thiadiazol-5-one pro-drug in which the - NH₂ group of any compound listed below is replaced by a -NPQ group, where P and Q have the meanings given above:

35 3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (trans)3 -(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 40 (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one.

45 13. The composition of any of claims 1-8, wherein the compound of the formula (VII), (VIII) or (IX) is an oxathiadiazole pro-drug in which the -NH₂ group of any compound listed below is replaced by a -NPQ group, where P and Q have the meanings given above:

50 C-[1-(2-Oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;
 (1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;
 C-[1-(2-Oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl] -methylamine;
 (trans)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methyl-
 amine;
 (1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (1R-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methyl-
 amine;
 (1R-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
 (1S-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methyl-
 amine;
 (1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methyl-


amine;
 $(1\alpha,3\beta,4\beta)C-[3,4\text{-Dimethyl-1-(2-oxo-2,3-dihydro-2}\lambda^4-[1,2,3,5]\text{oxathiadiazol-4-ylmethyl)-cyclopentyl}]$ -methyl-
 amine;
 $(S)C-[3,3\text{-Dimethyl-1-(2-oxo-2,3-dihydro-2}\lambda^4-[1,2,3,5]\text{oxathiadiazol-4-ylmethyl)-cyclopentyl}]$ -methylamine;
 $(R)C-[3,3\text{-Dimethyl-1-(2-oxo-2,3-dihydro-2}\lambda^4-[1,2,3,5]\text{oxathiadiazol-4-ylmethyl)-cyclopentyl}]$ -methylamine.

14. The composition of any of claims 1-8, wherein the compound of the formula (VII), (VIII) or (IX) is a pro-drug of formula (IX) in which the -NH₂ group of any compound listed below is replaced by a -NPQ group, where P and Q have the meanings given above:


4-methyl-2-(1H-tetrazol-5-ylmethyl)-pentyamine;
 3-(2-aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazol-5-one, HCl;
 3-(2-aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazole-5-thione, HCl;
 3-(3-amino-2-cyclopentyl-propyl)-4H-[1,2,4]oxadiazol-5-one.
 2-cyclopentyl-3-(2-oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-yl propylamine

15. The composition of claim 1 comprising a therapeutically effective amount of the following compound or a pharmaceutically acceptable salt thereof:

20




30 16. The composition of claim 1 comprising a therapeutically effective amount of the following compound or a pharmaceutically acceptable salt thereof:



18

17. The composition of claim 1 comprising a therapeutically effective amount of the following compound or a pharmaceutically acceptable salt thereof:

15



55

18. Use of any compound of any of the formulae (VII), (VIII) or (IX) as defined in any of claims 1-17 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of any of the following:

epilepsy; a faintness attack;
 hypokinesia; a cranial disorder;
 a neurodegenerative disorder; depression;
 anxiety; panic;
 pain; a neuropathological disorder;
 a digestive disorder.


19. A method for treating any of the disorders defined in claim 18, which comprises administering a therapeutically effective amount of a compound as defined in any of claims 1-17 to a human or animal in need of said treatment.

20. A compound of any of the formulae (VII), (VIII) or (IX) as defined in any of claims 1-17 or a pharmaceutically acceptable salt thereof, subject to the proviso that said compound is other than:


[1-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester; [1-(5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester; 4-methyl-2-(1H-tetrazol-5-ylmethyl)pentyl-carbamic acid tert-butyl ester; BOC-isobutyl GABA oxadiazolone; and BOC-isobutyl GABA oxadiazolone.

20 21. A method for making a compound of the formula (VII), (VIII) or (IX) as defined in any of claims 1-17, which comprises:

coupling a compound of the formula:



in which P and R¹ - R⁶ have the meanings given above and in which said compound is in the form of a free base or an ammonium salt with a compound of the formula (XIII)



or QCI, where (in each case) Q has the meaning given above.

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 201 240 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
09.04.2003 Bulletin 2003/15

(51) Int Cl.7: A61K 31/41, A61K 31/4245,
A61K 31/433, C07D 257/04,
C07D 271/07, C07D 285/08,
C07D 291/04, A61P 25/00,
A61P 25/08, A61P 25/28,
A61P 25/22, A61P 29/00,
A61P 1/00, A61P 25/24

(43) Date of publication A2:
02.05.2002 Bulletin 2002/18

(21) Application number: 01308061.9

(22) Date of filing: 21.09.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 31.10.2000 GB 0026578

(71) Applicant: WARNER-LAMBERT COMPANY
Morris Plains, New Jersey 07950 (US)




(72) Inventors:

- Bryans, Justin Stephen
Balsham, Cambridgeshire CB1 6DZ (GB)
- Williams, Sophie Caroline
Cambridge, Cambridgeshire CB1 7TX (GB)
- Blakemore, David Clive
Cambridge, Cambridgeshire CB1 8TH (GB)

(74) Representative: Cole, Paul
Lucas & Co.,
135 Westhall Road
Warlingham, Surrey CR6 9HJ (GB)

(54) **Heterocyclic derivatives useful as pharmaceutical agents**

(57) This invention relates to novel heterocyclic derivatives of the formula (VII), (VIII) or (IX)



in which P, Q, R¹ - R⁶, m and n are as defined in the specification, and to pharmaceutically acceptable salts thereof. The compounds and pharmaceutical compositions containing them are useful in the treatment of a range of disorders including epilepsy, faintness attacks, hypokinesia, cranial disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases and gastrointestinal disorders, especially irritable bowel syndrome.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 01 30 8061
shall be considered, for the purposes of subsequent
proceedings, as the European search report

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | CLASSIFICATION OF THE APPLICATION (Int.Cl.) |
|--|--|-------------------|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | |
| X | US 5 015 644 A (ROTH BRUCE D ET AL) 14 May 1991 (1991-05-14) * abstract; claims 1,7,27-31 * | 1-3,5,20 | A61K31/41 A61K31/4245 A61K31/433 C07D257/04 |
| D,Y | WO 99 31075 A (BRYANS JUSTIN STEPHEN ; HORWELL DAVID CHRISTOPHER (GB); KNEEN CLARE) 24 June 1999 (1999-06-24) compound 7, example 4 compound 9, example 5 * claims * | 1-13, 15-20 | C07D271/07 C07D285/08 C07D291/04 A61P25/00 A61P25/08 A61P25/28 A61P25/22 |
| D,Y | WO 99 31074 A (BRYANS JUSTIN STEPHEN ; HORWELL DAVID CHRISTOPHER (GB); KNEEN CLARE) 24 June 1999 (1999-06-24) compound 5, example 1 compound F, example 2 compound I, example 3 * claims * | 1-8,14, 18-20 | A61P29/00 A61P1/00 A61P25/24 |
| Y | MANFRED E. WOLFF: "BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, Fifth Edition" 1995, WILEY-INTERSCIENCE XP002219948 * page 172 - page 177 * | 1-20 | TECHNICAL FIELDS SEARCHED (Int.Cl.) A61K A61P C07D |
| INCOMPLETE SEARCH | | | |
| <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p> | | | |
| Place of search | Date of completion of the search | | Examiner |
| THE HAGUE | 8 November 2002 | | HOFF, P |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p> | | | |

European Patent
OfficeINCOMPLETE SEARCH
SHEET C

Application Number

EP 01 30 8061

Although claim 19 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched completely:
4,6-8,15-17

Claim(s) searched incompletely:
1-3,5,9-14,18-20

Reason for the limitation of the search:

Present claims 1-3,5,9-14,18-20 relate to an extremely large number of possible compounds (see in particular the definition of Q which includes any amine or amide-forming organic groups). Support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search for the first invention has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formulae (VII),(VIII) and (IX) with Q having the definition given in claims 4,6-8.

**CLAIMS INCURRING FEES**

The present European patent application comprised at the time of filing more than ten claims.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-20



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 01 30 8061

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-20

Pharmaceutical compositions comprising a compound of formulae (VII), (VIII) or (IX) and their use in the treatment of the disorders mentioned in claim 18. Compound of formulae (VII), (VIII) or (IX) other than those specifically recited in claim 20.

2. Claim : 21

Method of making a compound of the formulae (VII), (VIII) or (IX)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 8061

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-11-2002

| Patent document cited in search report | | Publication date | | Patent family member(s) | Publication date |
|---|---|---------------------|--|---|--|
| US 5015644 | A | 14-05-1991 | AT AU CA DE DE DK EP IE JP JP PT WO ZA | 110713 T 5675990 A 2054209 A1 69012116 D1 69012116 T2 474733 T3 0474733 A1 901983 A1 2799242 B2 4505617 T 94231 A 9015048 A1 9004231 A | 15-09-1994 07-01-1991 02-12-1990 06-10-1994 22-12-1994 21-11-1994 18-03-1992 02-01-1991 17-09-1998 01-10-1992 08-02-1991 13-12-1990 26-02-1992 |
| | | | AT AU AU CA DE DE DK EP ES FI GR IE JP JP JP NO NZ PH PT ZA | 79861 T 601846 B2 1657388 A 1296339 A1 3873992 D1 3873992 T2 297988 A 0293880 A1 2051797 T3 882588 A 3006297 T3 61716 B1 2575183 B2 63316761 A 882406 A ,B, 224670 A 24216 A 87622 A ,B 8803314 A | 15-09-1992 20-09-1990 08-12-1988 25-02-1992 01-10-1992 17-12-1992 03-12-1988 07-12-1988 01-07-1994 03-12-1988 21-06-1993 30-11-1994 22-01-1997 26-12-1988 05-12-1988 27-10-1989 10-04-1990 01-06-1988 31-01-1990 |
| WO 9931075 | A | 24-06-1999 | AU AU AU BR BR BR CA CA CA CN CN CN EP | 1392999 A 1455499 A 1796299 A 9813656 A 9814286 A 9814287 A 2304965 A1 2304967 A1 2304974 A1 1279673 T 1279667 T 1279674 T 1047678 A1 | 05-07-1999 05-07-1999 05-07-1999 10-10-2000 03-10-2000 03-10-2000 24-06-1999 24-06-1999 24-06-1999 10-01-2001 10-01-2001 10-01-2001 02-11-2000 |

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 8061

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-11-2002

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| WO 9931075 | A | EP 1045834 A1 | 25-10-2000 |
| | | EP 1045839 A2 | 25-10-2000 |
| | | HU 0004439 A2 | 28-10-2001 |
| | | HU 0100069 A2 | 28-12-2001 |
| | | HU 0100472 A2 | 28-09-2001 |
| | | JP 2002508352 T | 19-03-2002 |
| | | JP 2002508361 T | 19-03-2002 |
| | | JP 2002508362 T | 19-03-2002 |
| | | NO 20003037 A | 14-06-2000 |
| | | NO 20003038 A | 14-06-2000 |
| | | NO 20003039 A | 14-06-2000 |
| | | NZ 503963 A | 27-09-2002 |
| | | NZ 503980 A | 27-09-2002 |
| | | NZ 503981 A | 20-12-2002 |
| | | PL 341231 A1 | 26-03-2001 |
| | | PL 341291 A1 | 09-04-2001 |
| | | PL 348305 A1 | 20-05-2002 |
| | | TR 200001794 T2 | 23-10-2000 |
| | | TR 200001795 T2 | 21-11-2000 |
| | | TR 200001800 T2 | 21-03-2001 |
| | | WO 9931074 A2 | 24-06-1999 |
| | | WO 9931075 A1 | 24-06-1999 |
| | | WO 9931057 A1 | 24-06-1999 |
| | | ZA 9811464 A | 15-06-1999 |
| | | ZA 9811472 A | 07-07-1999 |
| | | ZA 9811474 A | 15-06-1999 |
| WO 9931074 | A 24-06-1999 | AU 1392999 A | 05-07-1999 |
| | | AU 1455499 A | 05-07-1999 |
| | | AU 1796299 A | 05-07-1999 |
| | | BR 9813656 A | 10-10-2000 |
| | | BR 9814286 A | 03-10-2000 |
| | | BR 9814287 A | 03-10-2000 |
| | | CA 2304965 A1 | 24-06-1999 |
| | | CA 2304967 A1 | 24-06-1999 |
| | | CA 2304974 A1 | 24-06-1999 |
| | | CN 1279673 T | 10-01-2001 |
| | | CN 1279667 T | 10-01-2001 |
| | | CN 1279674 T | 10-01-2001 |
| | | EP 1047678 A1 | 02-11-2000 |
| | | EP 1045834 A1 | 25-10-2000 |
| | | EP 1045839 A2 | 25-10-2000 |
| | | HU 0004439 A2 | 28-10-2001 |
| | | HU 0100069 A2 | 28-12-2001 |
| | | HU 0100472 A2 | 28-09-2001 |
| | | JP 2002508352 T | 19-03-2002 |

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 8061

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-11-2002

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| WO 9931074 A | | JP 2002508361 T | 19-03-2002 |
| | | JP 2002508362 T | 19-03-2002 |
| | | NO 20003037 A | 14-06-2000 |
| | | NO 20003038 A | 14-06-2000 |
| | | NO 20003039 A | 14-06-2000 |
| | | NZ 503963 A | 27-09-2002 |
| | | NZ 503980 A | 27-09-2002 |
| | | NZ 503981 A | 20-12-2002 |
| | | PL 341231 A1 | 26-03-2001 |
| | | PL 341291 A1 | 09-04-2001 |
| | | PL 348305 A1 | 20-05-2002 |
| | | TR 200001794 T2 | 23-10-2000 |
| | | TR 200001795 T2 | 21-11-2000 |
| | | TR 200001800 T2 | 21-03-2001 |
| | | WO 9931074 A2 | 24-06-1999 |
| | | WO 9931075 A1 | 24-06-1999 |
| | | WO 9931057 A1 | 24-06-1999 |
| | | ZA 9811464 A | 15-06-1999 |
| | | ZA 9811472 A | 07-07-1999 |
| | | ZA 9811474 A | 15-06-1999 |

THIS PAGE BLANK (USPTO)